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Review article
Systems biology: An emerging strategy
for discovering novel pathogenetic
mechanisms that promote
cardiovascular disease
Bradley A. Maron1 ,2*, Jane A. Leopold1
ABSTRACT
Reductionist theory proposes that analyzing complex systems according to their most
fundamental components is required for problem resolution, and has served as the cornerstone
of scientific methodology for more than four centuries. However, technological gains in the
current scientific era now allow for the generation of large datasets that profile the proteomic,
genomic, and metabolomic signatures of biological systems across a range of conditions. The
accessibility of data on such a vast scale has, in turn, highlighted the limitations of reductionism,
which is not conducive to analyses that consider multiple and contemporaneous interactions
between intermediates within a pathway or across constructs. Systems biology has emerged as
an alternative approach to analyze complex biological systems. This methodology is based on the
generation of scale-free networks and, thus, provides a quantitative assessment of relationships
between multiple intermediates, such as protein-protein interactions, within and between
pathways of interest. In this way, systems biology is well positioned to identify novel targets
implicated in the pathogenesis or treatment of diseases. In this review, the historical root and
fundamental basis of systems biology, as well as the potential applications of this methodology
are discussed with particular emphasis on integration of these concepts to further understanding
of cardiovascular disorders such as coronary artery disease and pulmonary hypertension.
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INTRODUCTION
The current era of human health and disease research is defined, in part, by an explosion
of technology that permits the measurement of biological data on a grand scale1.
Increased availability, cost-effectiveness, and access to gene chip arrays, whole genome
sequencing, metabolomic platforms, and next generation RNAseq among other
approaches has resulted in the application of these methodologies to profile the genetic
and molecular signature of virtually all biological mediums2,3 across normal and disease
states alike4. The magnitude of data derived from these methods, which in one recent
epigenetic study of myocardial infarction (MI) included an analysis of the protein-coding
regions for 9,793 patient genomes and single nucleotide variants in 64,132 samples5,
and the accelerating rate by which these methods are utilized in research have outpaced
the evolution of analytical strategies needed for their optimal interpretation. Specifically,
approaches that rely heavily on reductionism, such as association studies, cannot
account adequately for the complexity inherent to datasets of this scale1.
Network theory, in turn, leverages mathematical modeling to quantify multiple,
simultaneous interactions between variables (e.g., interactome). This method allows
for the graphical depiction of relationships across a range of subcellular components
(e.g., protein-protein, mRNA-protein, miRNA, others), and, therefore, is not limited by
a particular cell type, species, or pathway 6. Organizing networks further according to
connectivity patterns provides a hierarchical basis of the associations within parts of a
pathway or between pathways (Figure 1). Enriching networks by integrating gene sets
linked to a specific pathophenotype may be used to narrow assessments of interaction
clusters7. Overall, these strategies allow for a robust, but structured approach to
integrating, depicting, and analyzing big data for the purposes of understanding better
the interactions that underlie complex pathophenotypes.
Figure 1. Network topography. (A) In a random network, the majority of nodes shares a similar
number of links, and is analogous to the United States highway system in which cities are represented
as nodes and interconnecting roads are represented as links. (B) In non-random networks, such as in
biological systems, and, as is represented in this illustration the hub-spoke system of air travel patterns,
a minority of nodes are highly connected. (C) This characteristic establishes a hierarchy based on node
connectivity, which is grouped by convention in ascending order of complexity as: node, hub, module and
neighborhood. These levels of connectivity, in turn, may be topographical within a network, indicate a
common biological function, or grouped according to association with diseases. Figure adapted from6,37
with permission pending.
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HISTORICAL PERSPECTIVE: REDUCTIONISM IN SCIENCE
The French philosopher, mathematician, and physicist René Descartes is often referred to
as the father of reductionism, based largely on his ‘‘Rules for the direction of the mind’’
written originally in 16288, which posited 12 rules of scientific methodology. Among
them, rules V and VI stipulated problem resolution is best achieved through ‘intuitive
apprehension of all those that are absolutely simple’ and if ‘obscure propositions are
reduced step by step to those that are simpler.’ Descartes applied this rationale to his
workings that would ultimately serve as the basis for contemporary geometry, algebra,
and physics. In fact, this form of deductive, rule-based reasoning was utilized by many
of the great scientists and meta-scientists from the classical and contemporary eras,
including Galileo Galilei (astronomy; 1564–1642), Sir Isaac Newton (physics; 1643–1727),
Immanuel Kant (philosophy, 1724–1804), and, perhaps most relevant to biology, Sir
Charles Darwin in his theory of natural selection (1809–1882).
In the latter part of the 20th century, however, some challenged the appropriateness of
law-based theory to biological sciences9. The reasoning for this skepticism was based,
in part, on the identification of the following dilemmas: (i) reductionism implies that
rules affect all components of a system similarly, which is unlikely to be the case in living
organisms in vivo, and (ii) the sole focus of an analysis on fundamental components
of a biological system may not be possible or warranted. For example, assessing
phenotype expression according to genetic variability alone does not account for
post-transcriptional regulation of RNA or post-translational modification of proteins,
despite the staggering frequency of these events reported in proteome studies10 and
the importance of these regulatory mechanisms in determining physiologic and disease
states11–13. Furthermore, reductionist methodologies may have a number of important
unintended consequences in applied experimental biology. By narrowing the scope of
study solely to a single pathway or specific interaction between two intermediaries, the
effects of perturbations to the larger system are often unaccounted for (or overlooked).
This, in turn, has important ramifications when considering the translational relevance
of a drug or effector from studies in vitro to investigations in vivo or clinical trials. It has
been proposed, for example, that this principal may underlie the failure of folic acid
and B-vitamin supplementation to abrogate the cardiovascular risk associated with
hyperhomocysteinemia14 despite numerous epidemiologic reports in patients supporting
mechanistic data demonstrating that folic acid treatment limits the adverse effect of
homocysteine on endothelial dysfunction, atherogenesis, and thrombosis15. In these
studies, however, the pro-proliferative, tumorigenic, and diverse metabolic effects of
folic acid/B-vitamins were not generally considered16 (Figure 2). Thus, the possibility
remains that those or other untested (and potentially detrimental) consequences of
these therapies may account for the failure of folic acid/B-vitamin therapy to improve
outcome in randomized clinical trials17.
NETWORK THEORY IN APPLIED BIOLOGICAL SCIENCES
In random networks, the density of links (e.g., connections) between nodes (e.g., entities)
follows a Poisson (normal) distribution (Figure 1A). In this configuration, the majority
of nodes share a similar degree of connectivity, and highly connected nodes are not
common6,18. However, in biological networks (among other naturally occurring network
types), the relationship between nodes and links appears to be quite different. Jeong
and colleagues19 constructed a protein-protein interactome based on S. cerevisiae
proteome data and demonstrated the probability that a given protein interacts with other
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Figure 2. The biochemical pathway regulating homocysteine metabolism presented to scale within global mammalian metabolism.
Despite numerous basic, translational, and epidemiological scientific reports establishing a link between hyperhomocysteinemia
and cardiovascular disease risk, folic acid/B-vitamin supplementation to reduce plasma homocysteine levels is not associated with
improved outcome in clinical trials. (A) Mechanistic data demonstrating the beneficial effects of folic acid/B-vitamins on homocysteine-induced
vascular dysfunction are derived largely from studies focusing on factors directly relevant to homocysteine biochemistry. (B–D) However,
this reductionist approach does not account for the consequences of folic acid or B-vitamins on off-target pathways that are connected to
homocysteine and include intermediaries that regulate cell proliferation and survival. To consider the effects of folic acid/B-vitamins on
homocysteine metabolism and other pathways, a systems level approach is required.
proteins follows a power law, which was a finding that was confirmed in a bacterium
protein interactome, among other biological interactomes20. That is, a few nodes share
the property of high connectivity, while a greater number of nodes share the property
of low connectivity. These observations suggested that the relationship between nodes
and link density in biological networks is not stochastic, but is based on non-random
order. Indeed, subsequent work has demonstrated an inverse relationship between the
number of nodes and the number of links associated with each node indicating that there
is hierarchical order of connectivity with respect to function for nodes within a biological
network19,21. Furthermore, the number of links correlates positively with the biological
importance of a node, as removal of highly connected nodes corresponds to an increase
in organism lethality19. This concept can be expressed by betweeness centrality, which
reflects the number of shortest paths through a given node and is used to identify
important or essential nodes within a network22,23. While this may seem to suggest that
gene mutation (i.e., node deletion) is the principal driver of phenotype expression, this
is, in fact, an uncommon occurrence24. By contrast, network perturbation that occurs
through disruption of connectivity pathways via transcriptional, post-translational, and
environmental effects is more likely to account for expression of complex diseases25–27.
Peri and colleagues constructed the first human protein interactome by establishing
24,385 binary protein-protein interactions, which was based on manual curation of the
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literature describing physical interactions between proteins discovered primarily from in
vitro and in vivo experiments28. The same group later supplemented this database with
novel protein-protein interactions derived from several additional protein databases29–31.
They next analyzed the relationship between protein interactions according to subcellular
compartment and their relative proximity within the network. They observed differences
in connectivity patterns according to organelle and within specific biochemical
pathways32. These findings contributed to a larger set of observations indicating that
levels of organization within networks exist based on common biochemical, cellular,
functional, and phenotypic threads33–36.
Subsequently, nomenclature for grouping based on ascending order of clustering scale
has been proposed: node<hub<module<neighborhood, in which hubs represent highly
connected nodes, modules define groups of highly connected nodes in close proximity to
one another, and neighborhoods represent locally densely connected modules relative to
the larger interactome37,38. These associations are commonly topographical (within the
network), functional (in association with a common biochemical pathway), or disease-
associated (related to a particular pathophenotype)6.
Recently, Menche and colleagues39 focused attention on the validation of disease
modules within the consolidated human interactome, which is a collection of all
biologically relevant molecular interactions35,39–41. They compiled 141,296 physical
interactions between 13,460 proteins derived from experimental data involving protein-
protein interactions and interactions along metabolic and kinase-substrate pathways.
They next analyzed these data according to the relationship between pathways and 299
human diseases. By developing a mathematical code to abridge deficiency in the pool of
known disease-associated genes, the investigators were able to identify disease modules
while acknowledging that the current version of the consolidated human interactome
remains incomplete (Figure 3). They observed that the position of two disease modules in
this analysis was not random and, in fact, predicted biological and clinical similarities
based on overlap between modules for gene ontology, gene co-expression, clinical
symptoms, and probability of disease co-morbidity occurrence39. Taken together, these
findings validate the translational relevance of molecular interaction mapping, illustrate
the biological continuum spanning related pathophenotypes, and place into close
proximity diseases considered previously to be unrelated (e.g., glioma and myocardial
infarction).
SYSTEMS BIOLOGY IN CARDIOVASCULAR MEDICINE
Coronary artery disease
Reports leveraging systems biology to study the basis of human disease are populating
the medical literature at an accelerating rate42, and include reports on chronic
obstructive pulmonary disease43, solid tumor cancer44, gastrointestinal disorders45, and
pharmacotherapeutics46 among other areas47. Most relevant to cardiovascular medicine,
systems biology has been used to decipher the interactions between pathways that
regulate inflammation, cell proliferation, apoptosis, thrombosis, and fibrosis in relation
to diseases of the myocardium, pulmonary circulation, and systemic vasculature.
For example, Liu and colleagues performed a gene co-expression network
analysis recently using publically available microarray data acquired from peripheral
blood samples in patients with coronary artery disease (CAD)48. In this analysis, 3711
differentially expressed genes were segregated into 21 modules, and glucose-6-
phosphate dehydrogenase (G6PD) emerged as a highly connected node within
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Figure 3. (A) A 3-dimensional representation of the relationship between diseases in the
consolidated human interactome by Meche and colleagues39. In this analysis, the physical distance
between diseases is proportional to the shortest distance between closely connected protein pairs
across disease modules. Diseases whose modules (spheres) overlap are predicted to have a common
molecular pathobiology. (B) This methodology identified unexpected overlap between certain diseases,
such as hepatic cirrhosis, asthma, and celiac disease (left ). A network-level map demonstrates the
biological/immunological basis of overlap between in the asthma-celiac disease network-neighborhood.
Figure and legend reproduced with some modifications from39 with permission pending.
the principal module. These data, which depict G6PD as an important hub in the
pathogenesis of CAD, are in support of prior experimental data implicating deficient
levels of this antioxidant enzyme as a cause of endothelial dysfunction, vascular stiffness,
and systemic hypertension49–51. In related work from the Stockholm Atherosclerosis Gene
Expression (STAGE) study, unbiased two-way clustering analytics performed on mRNA
data from visceral fat and atherosclerotic lesions from patients was used to predict CAD
severity52. The transendothelial migration of leukocytes (TEML) pathway as well as the
LIM domain binding 2 protein emerged from this analysis as important targets linked to
clinically expressed CAD, although confirmatory experimental data in support of these
findings remain forthcoming.
Others have utilized networks for the purpose of determining prognosis following
MI53,54. The ‘my-inflamome,’ for example, is an interactome that included 2,595 proteins
and 6,181 interactions based on seed genes related to inflammatory biomarkers used in
the clinical management of MI patients55. From this, 21 highly-interconnected modules
were described according to their association with key biological processes (e.g., post-
translational protein modification, apoptosis, etc.). Combinations of modules and highly
connected nodes were entered into supervised computational and logistical regression
analyses to identify Tissue Necrosis Factor-α associated factor (TRAF2), SHKBP binding
protein-1 (SHKBP1), and Ubiquitin B (UBC ) as genes that may prognosticate clinical
outcome (defined as favorable [LVEF >40% post-MI] vs. unfavorable [LVEF <40% post-MI]).
Systems approaches are also being increasingly utilized to explore novel pathogenetic
mechanisms underlying primary cardiomyopathies, including fibroblast-myocyte
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interactions56, the transcriptomic basis for cardiomyocyte remodeling57, biomarker
identification in viral myocarditis58, and the proteomic basis of ischemic and reperfusion
myocardial injury54,59. In some cases, systems biology has been leveraged to critically
analyze data derived from genome-wide association studies (GWAS) reporting genetic
variants in cardiomyopathy. For example, Backes and colleagues60 reviewed data on
∼280,000 gene variants from 909 dilated cardiomyopathy patients and 2,120 controls,
and identified enrichment pathways (using the Kyoto Encyclopedia of Genes and
Genomes [KEGG] database) containing variants that were highly statistically significant
between patient groups. From this analysis, focus was directed to nucleotide excision
repair-related pathways. In particular, RAD23B, which regulates DNA damage recognition
and base excision repair, emerged as a candidate gene in this analysis. However, the
relevance of RAD23B or other genes implicated in this study to cardiomyopathy requires
further validation experimentally.
Pulmonary vascular disease
Pulmonary hypertension is defined currently by a mean pulmonary artery pressure ≥ 25
mmHg assessed by cardiac catheterization performed supine at rest61, and often occurs
in the setting of left heart disease, parenchymal lung disease, or thromboembolism.
Rarely, patients with PH that occurs due to interplay between molecular and genetic
factors in the absence of other comorbidities are reclassified as having pulmonary
arterial hypertension (PAH)62. In clinical practice, however, overlap between pulmonary
hypertension sub-groups is common, which may confound diagnosis and treatment
decision-making63,64. Therefore, there is an increasing emphasis on studying the
molecular basis of pulmonary hypertension in order to delineate pulmonary vascular
from other forms of cardiopulmonary diseases65,66, as well as to predict treatment-
responsiveness clinically67.
Systems biology has been utilized to characterize networks that regulate pulmonary
vascular remodeling and the development of PAH. Activation of soluble guanylyl cyclase
(sGC) by nitric oxide (NO) stimulates the conversion of GTP to cGMP, which, in turn, is a
potent antimitogenic second messenger that promotes vascular smooth cell relaxation.
Hydrolysis of cGMP to inactive 5’-GMP by phosphodiesterase type-V (PDE-V) is an
endogenous counter-regulatory mechanism controlling NO bioactivity. However,
diminished NO bioavailability and impaired NO-sGC signaling due, in part, to increased
pulmonary vascular oxidant stress68 are associated with endothelial dysfunction,
increased vascular smooth muscle cell proliferation, thrombosis, and vascular fibrosis
that contribute to adverse vascular remodeling and pulmonary hypertension in PAH63.
Although PDE-V inhibition and other novel direct NO delivery systems69 provide benefit
to PAH patients70, the optimal strategy for inducing maximal NO bioactivity is not
established. By modeling each step of the NO-sGC-cGMP reaction (12 molecular species
and 12 rate constants), however, the effect of oxidation on single reactions, reaction
pairs, or reaction trios was calculated recently to address this issue with respect to
the NO-sGC-cGMP pathway in pulmonary artery smooth muscle cells (Figure 4). This
approach identified sGC oxidation, NO dissociation from sGC, and PDE-mediated
hydrolysis of cGMP as a collective is the principal enzymatic regulator of NO bioactivity
in vitro, and sheds important new light on the potential value of a systems approach to
pharmacology in cardiopulmonary disease71.
Systems biology has also been used to identify novel pathogenetic mechanisms
controlling vascular remodeling in PAH. Parikh and colleagues generated a pulmonary
hypertension network by mapping 131 published genes associated with the development
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Figure 4. Nitric oxide-cGMP signaling. The vasodilator and anti-mitogenic molecule nitric oxide (NO)
may be synthesized endogenously by upregulation of NO synthase enzymes or enzymatic conversion
from nitrite, as well as exogenously by pharmacotherapeutic NO donors. The principal NO target in
vascular cells is the heterodimeric enzyme soluble guanylyl cyclase (sGC), which converts GTP to
the second messenger cGMP. Under conditions of increased oxidant stress, sGC may be oxidized to
inhibit sGC sensing by NO that impairs normal NO-dependent vascular smooth muscle cell relaxation.
Alternatively, cGMP may be hydrolyzed by phosphodiesterases to counter-regulate NO bioactivity.
Predictions using a systems approach that considered reaction kinetic combinations for various steps
in this biochemical pathway identified k1,k3, and k10 (red arrows) collectively as an optimal target to
modulate NO-cGMP signaling. cGMP, cyclic guanosine 3′, 5′-monophosphate; GMP, guanosine-5′-
monophosphate; GTP, guanosine-5′-triphosphate; H2O2, hydrogen peroxide; NAC, N-acetylcysteine;
NO., nitric oxide; NOx, oxidized (inactive) nitrogen oxides; PDE, phosphodiesterase; SNAP, S-Nitroso-
n-nacetylpenicillamine; sGC, soluble guanylyl cyclase. Adapted with some modifications from71 with
permission pending.
of pulmonary hypertension to the consolidated human interactome72. An algorithm-
based approach was then used to predict miRNA regulation of the PH-associated
genes, which allowed for rank-ordering of 29 miRNA groups based on their anticipated
regulation of pulmonary hypertension-relevant pathways, which in this analysis involved
gene sets associated with hypoxia, inflammation, and bone morphogenetic protein-
signaling. The investigators identified miR-21 targeting of Rho/Rho kinase from this
approach as potentially relevant to pulmonary hypertension. This prediction was then
validated by demonstrating miR-21-dependent upregulation of Rho/Rho kinase in
cultured pulmonary endothelial cells, which corresponded to impaired endothelial nitric
synthase expression in vitro and vascular remodeling and pulmonary hypertension
in vivo. Similar approaches have been utilized to understand further mechanisms
underpinning the fibrotic and the contractile vascular phenotype characteristics of
PAH73–75.
CONCLUSIONS
The current era of scientific investigation, in which large-scale datasets are used to
identify novel genetic or molecular etiologies for disease expression, has brought to
Page 9 of 13
Maron & Leopold. GCSP 2016:27
light some limitations in the application of association studies and other reductionist
analytical methods. Network theory is an evolving strategy that utilizes mathematical
modeling to illustrate simultaneously numerous interactions between subcellular
components. Discovering and reporting relationships based on hierarchical levels
of connectivity assists in stratifying network nodes according to importance, and
provides a scale-free model by which to pursue unexpected targets involved in disease
pathobiology or treatment. Currently, systems biology methods have been reported
across various areas within cardiovascular disease research, including coronary artery
disease and pulmonary hypertension. Coupling this and other similar approaches with
experimental methods to validate network findings is likely to increase the translational
potential of observations in silico to clinically relevant findings for patients affected by
cardiovascular disease.
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miRNA microRNA
MI myocardial infarction
G6PD glucose-6-phosphate dehydrogenase
CAD coronary artery disease
KEGG Kyoto Encyclopedia of Genes and Genomes
GWAS genome-wide association study
PAH pulmonary arterial hypertension
NO nitric oxide
PDE phosphodiesterase
cGMP Cyclic guanosine monophosphate
GMP guanosine triphosphate
sGC soluble guanylyl cyclase
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